AR063219A1 - Derivados de azetidinona, una composicion que los comprende y su uso en el tratamiento del dolor y de trastornos del metabolismo lipidico. - Google Patents

Derivados de azetidinona, una composicion que los comprende y su uso en el tratamiento del dolor y de trastornos del metabolismo lipidico.

Info

Publication number
AR063219A1
AR063219A1 ARP070104078A ARP070104078A AR063219A1 AR 063219 A1 AR063219 A1 AR 063219A1 AR P070104078 A ARP070104078 A AR P070104078A AR P070104078 A ARP070104078 A AR P070104078A AR 063219 A1 AR063219 A1 AR 063219A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
aryl
group
optionally
Prior art date
Application number
ARP070104078A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR063219A1 publication Critical patent/AR063219A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados de azetidinona, a composiciones que comprenden un derivado de azetidinona y a su uso para tratar o prevenir un trastorno del metabolismo lipídico, dolor, diabetes, una afeccion vascular, desmielinizacion o enfermedad hepática grasa no alcoholica. Reivindicacion 1: Un compuesto que tiene la formula (1) o su sal, solvato, éster, profármaco o estereoisomero aceptable para uso farmacéutico, donde: R1 es H, alquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, difenilmetilo, cicloalquilalquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo o -alquilen-C(O)N(alquilo)2, donde un grupo alquilo, arilo o heteroarilo puede estar opcional e independientemente sustituido con uno o más de los siguientes grupos: -(C=NO-alquil)CH3, -NC(O)NH2, -NC(O)NH(alquilo), -NC(O)N(alquilo)2, -SO2NH2, -SO2NH(alquilo), -SO2N(alquilo)2, -CF3, -OH, -halo, -CN, -alcoxi, -C(O)O-alquilo, -S(O)alquilo, -SO2-alquilo o -P(O)(O-alquilo)2, y un grupo arilo además puede estar opcional e independientemente sustituido con uno o más grupos alquilo; R2 es H, alquilo, cicloalquilo, arilo, arilalquilo, heteroarilalquilo, heterocicloalquilo, heterocicloalquilalquilo, R6-A-, alquil-O-C(O)-, (alquil)2N-alquilen-C(O)-, (alquil)2-N-C(O)-alquilen-C(O)-, CN-alquilen-C(O)-, alquil-Oalquilen-C(O)-, alquil-C(O)-alquilen-C(O)-, alquil-C(O)-NH-alquilen-C(O)-, alquil-NH-C(O)-, aril-NH-C(O)-, alquil-O-C(O)-alquilen-C(O)-, alquil-O-C(O)-cicloalquilen-alquilen-, NH2-C(O)-NH- alquilen-C(O)-, NH2-C(O)-alquilen-C(O)-, alquil-C(O)-NH-alquilen-S-alquilen-C(O)-, alquil-O-C(O)-alquilen-C(O)-, alquil-S-alquilen-C(O)-, alquil-C(O)-cicloalquilen-alquilen-C(O)-, alquil-S-alquileno-, (-NHC(O)alquil)C(O)-, alquil(-C(O)Oalquil)-NH- C(O)- o -C(O)-alquilen-N(R6)2-; o alquil-S-alquilen(-NHC(O)alquil-C(O)-, donde un grupo alquilo o arilo puede estar opcional e independientemente sustituido con uno o más de los siguientes grupos; -(C=N-O-alquil)CH3, -NH-C(O)NH-alquilo, -C(O)NH2, - CN, -C(O)NH-alquilo, -C(O)O-alquilo, -C(O)H, -C(O)OH, -NC(O)NH2, -NC(O)NH(alquilo), -NC(O)N(alquil)2, -SO2NH2, -SO2NH(alquilo), -SO2N(alquilo)2, -CF3, -OH, -halo, haloalquilo, -CN, -alcoxi, -C(O)O-alquilo, -S(O)alquilo, -SO2-alquilo o -P(O)(O- alquilo)2, y un grupo arilo además puede estar opcional e independientemente sustituido con uno o más grupos alquilo; R3 es H, alquilo, arilo, arilalquilo, arilalquenilo, arilalquinilo, NH-arilalquilo, arilalcoxi, ariltio, arilalquiltio, arilcarbonilo, ariloxi, cicloalquilo, arilsulfonilo, heteroarilo, heteroarilalquilo, heteroarilalquenilo, heteroarilalquinilo, heteroarilalcoxi, heteroariloxi o heteroarilsulfonilo, donde un grupo alquilo o arilo puede estar opcional e independientemente sustituido con uno o más de los siguientes grupos; -(C=N-O-alquil)CH3, -NC(O)NH2, -NC(O)NH(alquilo), -NC(O)N(alquilo)2, -SO2NH2, -SO2NH(alquilo), -SO2N(alquilo)2, -CF3, -OH, -halo, -CN, -alcoxi, -C(O)O-alquilo, -S(O)alquilo, -SO2- alquilo o -P(O)(O-alquilo)2, un grupo arilo puede estar opcional e independientemente sustituido con uno o más grupos alquilo, y un grupo heteroarilo puede estar opcional e independientemente sustituido con uno o más grupos arilo o heteroarilo. cada aparicion de R4 y R5 es independientemente -C(R7)2-, donde el átomo de carbono en el anillo de un grupo y el átomo de carbono en el anillo de un grupo puede estar opcionalmente unido por un grupo -CH2-CH2-; cada aparicion de R6 es independientemente alquilo. alquenilo, arilo, heteroarilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, cicloalquenilo, heterocicloalquenilo, cicloalquilo benzofusionado, heterocicloalquilo benzofusionado, o heterocicloalquenilo benzofusionado; cada aparicion de R7 es independientemente -H, -alquilo, -CN u -OH; A es -C(O)-, -OC(O)-, -alquilen-C(O)-, -O-alquilen-C(O)-, -C(O)-alquilen-C(O)-, -C(O)-NHCH2-C(O)-, -C(O)-N(alquil)-CH2-C(O)-, -alquilen-, -alquenileno, -alquenilen-C(O)-, grupo de formula (2), -O- C(O)-alquilen-C(O)-, -cicloalquilen-NH-C(O)-, -NHC(O)-, -alquilen-NHC(O)-, -alquilen-C(O)NH-alquilen-C(O)-, -alquilen-C(O)NH-alquilen-C(O)-, -C(O)-NH-alquilen-C(O)-, -alquilen-O-alquilen-C(O)-, -alquilen(alcoxi)-C(O)- o -S-alquilen-C(O)-, donde un grupo A está unido al átomo de nitrogeno al cual está unido mediante un grupo C(O) terminal; u es un entero que varia de 0 hasta 3; y v es un entero que varía de 0 hasta 3; de modo que la suma de u y v es de 3 a 5, de modo que el compuesto de formula (1) no es un compuesto de formula (1A), (1B), (1C) o (1D) como se expone en la memoria descriptiva anterior.
ARP070104078A 2006-09-15 2007-09-14 Derivados de azetidinona, una composicion que los comprende y su uso en el tratamiento del dolor y de trastornos del metabolismo lipidico. AR063219A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84507506P 2006-09-15 2006-09-15

Publications (1)

Publication Number Publication Date
AR063219A1 true AR063219A1 (es) 2009-01-14

Family

ID=39145026

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104078A AR063219A1 (es) 2006-09-15 2007-09-14 Derivados de azetidinona, una composicion que los comprende y su uso en el tratamiento del dolor y de trastornos del metabolismo lipidico.

Country Status (9)

Country Link
US (1) US7884080B2 (es)
EP (1) EP2061792A2 (es)
JP (1) JP2010503677A (es)
CN (1) CN101583612A (es)
AR (1) AR063219A1 (es)
CA (1) CA2663502A1 (es)
MX (1) MX2009002921A (es)
TW (1) TW200819450A (es)
WO (1) WO2008033464A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2663500A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
JP2010503678A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション アゼチジノン誘導体およびその使用方法
MX2009002922A (es) * 2006-09-15 2009-04-01 Schering Corp Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
WO2008033431A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090092693A1 (en) * 2007-10-05 2009-04-09 Mady Attila Platelet manipulation to prevent and treat endovascular disease and its sequelae, to prevent and treat arrhythmias and to prevent malignancy
JP2011519926A (ja) * 2008-05-05 2011-07-14 ウィンスロップ−ユニバーシティー ホスピタル Ｃｏｘ阻害薬の心血管系リスク因子の改善方法
EP2331571B1 (en) 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
SG183265A1 (en) 2010-02-11 2012-09-27 Univ Northwestern Secondary structure stabilized nmda receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TWI562977B (en) 2010-11-05 2016-12-21 Bayer Ip Gmbh Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation
JP6463631B2 (ja) 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Ｇｐｒ−１１９のモジュレータとしての新規化合物
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SG11201401816SA (en) 2011-10-28 2014-05-29 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EA201891154A1 (ru) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
TWI726205B (zh) * 2012-04-26 2021-05-01 德商拜耳作物科學公司 N-(5-氯-2-異丙基苄基)環丙胺
AU2013321918B2 (en) 2012-09-27 2018-05-10 Kowa Company, Ltd. Therapeutic agent for dyslipidemia
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
EA201591405A1 (ru) 2013-01-29 2017-05-31 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
SI3514158T1 (sl) 2013-01-29 2023-03-31 Aptinyx Inc. Spirolaktamski modulatorji NMDA-receptorja in njihove uporabe
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
KR20160002773A (ko) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
WO2015111971A1 (ko) * 2014-01-23 2015-07-30 동국대학교 산학협력단 Gpr119 리간드를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
EP3364993B1 (en) 2015-10-22 2022-11-09 Cavion, Inc. Methods for treating angelman syndrome
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3031537A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
IL264496B (en) 2016-08-01 2022-09-01 Aptinyx Inc Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
KR102642063B1 (ko) 2017-02-15 2024-03-04 카비온, 인코포레이티드 칼슘 채널 억제제
MX2019012818A (es) 2017-04-26 2020-07-14 Cavion Inc Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
AU2019215058A1 (en) 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2021003706A (es) 2018-10-03 2021-11-04 Cavion Inc Tratamiento del temblor esencial usando (r)-2-(4-isopropilfenil)-n -(1-(5-(2,2,2- trifluoroetoxi)piridin-2-il)etil)acetamida.
BR112021015809A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Resposta dependente de genótipo e dose a um asbti em pacientes com deficiência de bomba de exportação de sal biliar
BR112022000429A2 (pt) 2019-07-11 2022-03-29 Praxis Prec Medicines Inc Formulações de moduladores do canal de cálcio tipo t e métodos de uso dos mesmos
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692515A (en) * 1984-09-24 1987-09-08 Pennwalt Corporation Adamantane-spirolactams
US5215994A (en) 1990-09-25 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic derivatives
US5130425A (en) * 1990-10-12 1992-07-14 American Home Products Corporation Spiro-lactams and analogs thereof useful as aldose reductase inhibitors
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
GB9201789D0 (en) 1992-01-28 1992-03-11 Fujisawa Pharmaceutical Co Heterocyclic derivatives
DE69307131T2 (de) 1992-04-03 1997-04-24 Gist Brocades Nv Selektive n-acylation von aminoalkoholen
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
FR2710337B1 (fr) 1993-09-23 1995-12-08 Gerard Coquerel Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5648484A (en) * 1995-03-07 1997-07-15 Schering Corporation Catalytic enantioselective synthesis of a spriofused azetidinone
DE69712745T2 (de) 1996-01-23 2002-10-31 Novartis Ag, Basel Pyrrolopyrimidinen und verfahren zu deren herstellung
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2799756B1 (fr) 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE10050322A1 (de) 2000-10-10 2002-04-11 Brose Fahrzeugteile Türmodulträger
AU2002216097B2 (en) 2000-12-21 2006-09-07 Sanofi-Aventis Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
JP2003214113A (ja) 2002-01-28 2003-07-30 Toshiba Corp 地熱タービン
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
EP1635813A4 (en) 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7396940B2 (en) 2003-10-23 2008-07-08 Hoffmann-La Roche Inc. Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid
US20050096307A1 (en) 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
US7291728B2 (en) * 2004-05-10 2007-11-06 Laboratories Del Dr. Esteve, S.A. Spirolactams and their synthesis
EP1598336A1 (en) * 2004-05-20 2005-11-23 Laboratorios Del Dr. Esteve, S.A. Regioselective hydroxylation, functionalisation and protection of spirolactams
AU2005275181A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2010503678A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション アゼチジノン誘導体およびその使用方法
CA2663500A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
MX2009002922A (es) * 2006-09-15 2009-04-01 Schering Corp Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
WO2008033447A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
MX2009002920A (es) * 2006-09-15 2009-04-01 Schering Corp Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
WO2008033431A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders

Also Published As

Publication number Publication date
WO2008033464A3 (en) 2008-05-15
EP2061792A2 (en) 2009-05-27
MX2009002921A (es) 2009-04-01
US20080076751A1 (en) 2008-03-27
CN101583612A (zh) 2009-11-18
WO2008033464A2 (en) 2008-03-20
US7884080B2 (en) 2011-02-08
CA2663502A1 (en) 2008-03-20
JP2010503677A (ja) 2010-02-04
TW200819450A (en) 2008-05-01

Similar Documents

Publication Publication Date Title
AR063219A1 (es) Derivados de azetidinona, una composicion que los comprende y su uso en el tratamiento del dolor y de trastornos del metabolismo lipidico.
AR062793A1 (es) Compuestos de azetidinona espirociclicos y metodos para su uso
AR081331A1 (es) Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
RU2020105929A (ru) Способы и композиции для модулирования сплайсинга
AR072559A1 (es) Amidas sustituidas, composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades mediadas por dgat1.
MA45223B1 (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
AR082985A1 (es) INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
AR039659A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR033525A1 (es) Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento
AR045651A1 (es) Derivados de tiazol como moduladores del receptor de cannabinoide
AR065996A1 (es) Derivados de pirimidindiona,composiciones farmaceuticas que los conitenen y usos en el tratamiento y/o prevencion de la obesidad, diabetes, dislipidemia entre otras patologias.
RU2008112202A (ru) Производные фенил-[1,2,4]-оксадиазол-5-она с фенильной группой, способы их получения и их применение в качестве фармацевтических средств
AR068503A1 (es) Derivados de amidas sustituidas, composicion farmaceutica y usos.
AR102799A1 (es) Profármacos de agonistas fenólicos de trpv1
AR076024A1 (es) Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
AR068695A2 (es) Uso de un compuesto de tiazol que comprende un derivado de tiazol para la fabricacion de un medicamento para la prevencion y el tratamiento de en-fermedades causadas por la produccion anormal de citocinas y/o la acele-racion de la adhesion de neutrofilos y/o la produccion anormal de tnf- alfa
AR046326A1 (es) Compuestos de heteroarilo de 6-miembros para el tratamiento de trastornos neurodegenerativos
AR073922A1 (es) 2- oxoquinoxalinas como bloqueadores de los canales de sodio tardios
AR071327A1 (es) Inhibidores de pkl y composiciones farmaceuticas que los contienen
AR068888A1 (es) Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp.
AR052328A1 (es) Derivados de 2 - alcoxi - 3, 4, 5 - trihidroxi - alquilamidas, composiciones farmaceuticas que las contienen, y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
AR043959A1 (es) Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos
AR067975A1 (es) Derivados de la n-bencil, n-arilcarbonilpiperazina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal